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A B S T R A C T
The purpose of this study is to report the ﬁrst nationwide protocol (Wuhan Protocol) developed by Chinese
Children’s Cancer Group and the results of multidisciplinary effort in treating hepatoblastoma. In this
study, we reported the ﬁnal analysis, which includes 153 hepatoblastoma patients in 13 hospitals from
January 2006 to December 2013. The 6-year overall survival and event-free survival rateswere 83.3 ± 3.1%
and 71.0 ± 3.7%, respectively, in this cohort. The univariate analysis revealed that female (P = 0.027), under
5 years of age (P = 0.039), complete surgical resection (P = 0.000), no metastases (P = 0.000), and delayed
surgery following neoadjuvant chemotherapy (P = 0.000) had better prognosis. In multivariate analysis,
male, 5 years of age or above, stage PRETEXT III or IV, and incomplete surgical resection were among the
some adverse factors contributing to poor prognosis. The preliminary results from this study showed
that patients who underwent treatment following Wuhan Protocol had similar OS and EFS rates com-
pared to those indevelopedcountries.However, theprotocol remains tobe further optimized in standardizing
surgical resection (including liver transplantation), reﬁning risk stratiﬁcation and risk-based chemotherapy.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatoblastoma (HB) is one of the most common liver malig-
nancies in children. Recent data showed that the incidence of HB
has increased by 2.18% annually in patients under 20 years of age.
Ninety percent of patients with liver malignancies under 5 years of
age were diagnosed with HB [1]. In the past, the main treatment for
HBwas surgical resection; however, complete tumor resection could
be achieved only in a few patients [2]. The use of chemotherapy
improved the survival rate dramatically since 1970s [3]. The multi-
disciplinary team (MDT), which included pediatric surgeons,
oncologists, radiologists, and pathologists, played an essential role
in HB treatment, with a survival rate of over 80% reported elsewhere
in the world [4]. However, there was no report on overall survival
(OS) and event-free survival (EFS) study in pediatric HB patients in
China. In 2006, XinHuaHospital Aﬃliated to Shanghai Jiao TongUni-
versity School ofMedicine developed a protocol and the preliminary
data showed a satisfactory survival rate in 12HBpatients [5]. In order
to improve the outcome in HB patients and standardize the
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treatment regimens in China, using protocols from Société
Internationale d’Oncologie Pédiatrique-Epithelial Liver Tumor Study
Group (SIOPEL) and Children’s Oncology Group (COG) as references,
Chinese Children’s Cancer Group (CCCG) developed the Multidisci-
plinary Treatment Guideline for Chinese Children with Hepatoblastoma
in thecityofWuhan,HubeiProvince, in2009, also referred toasWuhan
Protocol. This protocol focused on pre-operative chemotherapy and
MDT effort in treating HB patients; thirteen CCCGmember hospitals
adopted this protocol. The purpose of this study is to assess the fea-
sibility andeffectivenessof theﬁrstnationwideprotocol and the results
of multidisciplinary effort in treating HB in China.
Materials and methods
Inclusion and exclusion criteria
From January 2006 to December 2013, there were 162 cases of pediatric HB
treated in 13 CCCG member hospitals following Wuhan Protocol but 153 patients
were enrolled in this study. The enrollment criteria for patients in this study were:
(1) patients must be younger than 18 years of age; (2) patients had not had any che-
motherapy before inclusion; and (3) pathological diagnosis conﬁrmed by ultrasound-
guided ﬁne-needle biopsy or surgical resection. Patients with great risk for biopsy
at the onset were temporarily diagnosed with clinical ﬁndings, including age, clin-
ical history, physical examination, serum α-fetoprotein (AFP) level, and computed
tomography (CT) scan or magnetic resonance imaging (MRI). After two or more cycles
of neoadjuvant chemotherapy, the diagnoses of all patients were pathologically con-
ﬁrmed after a subsequent surgical tumor resection. Patients who underwent treatment
following Wuhan Protocol for less than one cycle of chemotherapy were excluded
from this study. The medical records of all enrolled cases were retrospectively re-
viewed, and their information (including medical history, physical examination, CT/
MRI images, serum AFP, chemotherapy regimens, surgery, and outcome) was collected
and veriﬁed by CCCG senior pediatricians and radiologists (CT/MRI images were used
to deﬁne the stage). The Ethics Committee of each individual hospital had re-
viewed and approved this study. The consent from each patient’s parents or legal
guardians was obtained before treatment.
Stage, pathology, and risk stratiﬁcation
Patients were classiﬁed using PRETEXT (pretreatment extent of disease) system
[6] before treatment and COG staging [7] after surgery. The stage of each patient
was veriﬁed by Dr. Yu-Hua Li, a CCCG senior pediatric radiologist from Xin Hua Hos-
pital Aﬃliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Based on WHO pathological diagnostic criteria [8], patients were divided into the
pure fetal pattern, the combined fetal and embryonal epithelial pattern, the mixed
epithelial and mesenchymal pattern, and other patterns (including the
macrotrabecular, the small cell undifferentiated and the mixed with teratoid feature
patterns). The paraﬃn sections from the tumor specimens of all patients were re-
viewed by Dr. Min-Zhi Yin, a CCCG senior pathologist at Shanghai Children’s Medical
Center, Shanghai, China.
To compare the treatment outcome among different risk groups withWuhan Pro-
tocol and provide the basis for risk-based chemotherapy in future revision of the
protocol, we retrospectively classiﬁed the patients into two groups based on the cri-
teria of SIOPEL risk stratiﬁcation [9,10]: standard-risk group and high-risk group.
Standard-risk is deﬁned as PRETEXT I, II or III, without any manifestation listed in
high risk group; high-risk is deﬁned as PRETEXT IV, or any PRETEXT stage with tumor
inﬁltration of the inferior vena cava (IVC)/hepatic veins (+V), portal vein (+P), ex-
trahepatic abdominal (+E), distant metastases (+M), the small cell undifferentiated
(SCU), AFP <100 ng/mL, or tumor rupture.
Treatment procedure
Patients who were diagnosed with HB and met the enrollment criteria were
treated following Wuhan Protocol. In this protocol (shown in Fig. 1), PRETEXT I pa-
tients were recommended to have surgical tumor resection followed by either two
or four courses of post-operative chemotherapy. The preferred regimen was C5V,
which consisted of cisplatin (90 mg/m2, >1 year old, or 3 mg/kg, <1 year old)
on day 1, vincristine (1.5 mg/m2 with a maximum dose of 2 mg) and 5-ﬂuorouracil
(600 mg/m2) on day 2.
All PRETEXT II, III, and IV patients usually received the same two courses of che-
motherapy (C5V regimen) after diagnosis, with a 21-day interval between two courses.
Patients’ AFP level and CT scan were repeated after the second course of chemo-
therapy (deﬁned as the ﬁrst evaluation). Based on the ﬁrst evaluation results, MDT
members made a decision as when to have surgery. If the patients had complete
surgical tumor resection, they were followed by either two or four courses of post-
operative chemotherapy (C5V regimen). The total courses of chemotherapy for these
cases were four to six.
Patients who could not undergo surgery after the ﬁrst evaluation would receive
two more courses of chemotherapy (C5V regimen). However, the patients whose
ﬁrst evaluation showed no response to initial chemotherapy (without reduced serum
AFP level or tumor size), or the tumor was progressing, were subsequently switched
to PLADO regimen. As an alternative regimen, PLADO was consisted of cisplatin
(80 mg/m2) on day 1, and doxorubicin (30 mg/m2/d) on day 2 and day 3. The results
of second evaluation by MDT after four courses of chemotherapy were used to de-
termine the proper time-point of surgery. Patients with complete surgical resection
received two to four more courses of post-operative chemotherapy. There would be
a total of six to eight courses of chemotherapy. Those patients whose tumors could
not be resected completely continued to receive twomore courses of PLADO regimen.
After the third evaluation, some of the patients underwent surgery and then re-
ceived two to four courses with C5V or PLADO regimen.
Those patients who had ﬁnished six courses of pre-operative chemotherapy, but
not responding to the chemotherapy as determined during the evaluations at dif-
ferent intervals, were excluded fromWuhan Protocol. These patients would be adjusted
with other regimens (e.g. C5VD, ICE, and cyclo/topo) based on drug sensitivity results;
each patient received an individual treatment plan.
Statistical analysis
Data statistics were performed using SPSS (Statistical Package for the Social Sci-
ences), version 19.0 (SPSS Inc, Chicago, IL, USA). Survival curves were estimated by
Kaplan–Meier method; the survival rates were reported as mean ± standard error
(SE). Log-rank test was used to analyze prognostic univariate. Variables with a P-val-
ue <0.05 in univariate analysis were entered into the multivariate Cox proportional-
hazards regression model. A P-value <0.05 was considered to be of statistical
signiﬁcance.
Follow-up
The last follow-up date for this study was May 31, 2015. Overall survival (OS)
was calculated as time (in months) from diagnosis to death of any cause. Event-
free survival (EFS) was calculated as time (inmonths) from deﬁnitive clinical diagnosis
to event happening (including disease progression, recurrence, abandonment or death
of any cause, whichever occurred ﬁrst). Complete remission (CR) means that there
is no evidence of tumor in CT or MRI, and normal serum AFP level for at least 4 weeks.
Partial remission (PR)means a decrease of at least 50% in size of all measurable lesions,
with no evidence of new lesions or progression in any lesion. Stable disease (SD)
refers to any remission without an increase in tumor size and new lesions. Progres-
sive disease (PD) refers to an increase of at least 25% in the size of any lesion, any
new lesion, or a rising AFP level. Lost to follow-up is deﬁned as that patient who
failed to be followed up for at least 6 months.
Follow-ups were conducted in patients’ primary hospital for at least 5 years from
the date of treatment completion or the cut-off date for this report. The AFP level
was checked monthly in the ﬁrst year of follow-up, then every three months in the
second year and third year, and every six months in the fourth and ﬁfth years. MRI
or CT scan was performed every two months in the ﬁrst year, every three months
in the second year, every six months in the third year, and annually during the last
two years.
Results
Patients’ characteristics
From January 2006 to December 2013, a total of 162 patients
from 13 CCCGmembermedical centers were registered for this study.
Nine cases were excluded from the cohort, of which 4 patients aban-
doned treatment (two of which abandoned treatment due to
ﬁnancial reasons and the other two suffered from heart failure), one
patient was misdiagnosed with HB (the patient was clinically di-
agnosed with HB, but the pathological result after a subsequent
surgery was conﬁrmed as yolk sac tumor after 4 cycles of chemo-
therapy), and 4 cases lacked complete documentations. Therefore,
153 cases were included, analyzed and reported in this study. The
group included 104 males and 49 females (the male to female ratio
was 2.1:1); themedian age at diagnosis was 16.0 (1.3–132.0) months,
median follow-up time was 52.9 (1.0–116.6) months. The demo-
graphic and clinical characteristics of 153 HB patients were listed
in Table 1. There were 6 (6/153, 3.9%) preterm patients and none
was very low birth weight infant.
Staging, metastases and risk stratiﬁcation
Patients were staged according to PRETEXT system before treat-
ment. The number of cases of PRETEXT I is 16 (10.4%), PRETEXT II
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is 29 (19.0%), PRETEXT III is 64 (41.8%), and PRETEXT IV is 44 (28.8%).
Among all cases, three patients had hepatic vein tumor inﬁltra-
tion and none had tumor rupture or portal vein involvement. After
surgical resection, 143 patients were classiﬁed based on COG system
subsequently with cases in stage I: 109 (76.2%), stage II: 11 (7.7%),
stage III: 8 (5.6%), and stage IV: 15 (10.5%) cases.
A total of 23 patients had metastasis at time of diagnosis, 18 pa-
tients (78.3%) had lung metastases, of which 2 also had brain or
hepatic vein involvement; 2 cases (8.7%) had hepatic vein metas-
tasis; 3 cases (13.0%) had bone, gall bladder, or ascites metastasis,
respectively.
Based on SIOPEL risk stratiﬁcation criteria, we retrospectively clas-
siﬁed all the patients into standard-risk group (n = 104) and high-
risk group (n = 49).
Treatment
Treatment path
Over half of the patients (99/153, 64.7%) received neoadjuvant
chemotherapy initially after diagnosis (Fig. 2), but only 89 pa-
tients could have surgical resection. Of those 89 patients, 4 (4.5%)
were treated with two courses of C5V regimen before surgery, 25
cases (28.1%) received four courses of C5V or PLADO regimen before
Fig. 1. Treatment plan of Wuhan Protocol. The protocol mainly includes two parts: (a) Patients with PRETEXT I stage will have primary surgery and post-operative chemo-
therapy; (b) PRETEXT II, III, or IV patients will have neoadjuvant chemotherapy, delayed surgery, and post-operative chemotherapy.
Table 1
Demographic and clinical characteristics of 153 HB patients.
Characteristics Case number, n (%)
Gender
Male 104 (68.0)
Female 49 (32.0)
Age
Under 5 years of age 143 (93.5)
5 years of age or above 10 (6.5)
Main clinical manifestations
Abdominal mass 122 (79.7)
Abdominal distention 11 (7.2)
Abdominal pain 10 (6.5)
Fever 6 (3.9)
Jaundice 4 (2.6)
Serum AFP level at diagnosis
<100 ng/mL 2 (1.3)
100–100,000 ng/mL 35 (22.9)
>100,000 ng/mL 116 (75.8)
Pathological subtypes
Pure fetal pattern 34 (22.2)
Fetal and embryonal 55 (35.9)
Epithelial and mesenchymal 50 (32.7)
Others 6 (3.9)
Unknown 8 (5.2)
Metastasis at the onset
With 23 (15.0)
Without 130 (85.0)
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resection, 33 cases (37.1%) had six courses of pre-operative che-
motherapy, and another 27 patients (30.3%) accepted more than six
courses of neoadjuvant chemotherapy, including individualized treat-
ment plan after six courses. The remaining 10 patients did not have
surgery; two died from primary disease and the other two died from
sepsis, 4 cases abandoned treatment due to primary disease pro-
gressing, and two patients manifested progressive disease after six
courses of chemotherapy. Fifty-four (35.3%) patients underwent sur-
gical resection after they were clinically diagnosed with HB. One
hundred and forty-three cases received post-operative chemother-
apy, 6 cases had a second surgery (including one relapsed in liver,
ﬁve had incomplete resection in ﬁrst surgical attempt).
Chemotherapy
One hundred and eight patients (70.6%) were treated only with
regimens per Wuhan Protocol, including 63 cases (58.3%) with C5V
regimen, others with both C5V and PLADO regimens. However, 46
patients (30.1%) showed no response (without reduced serum AFP
level or tumor size) to both C5V and PLADO treatment. Among them,
27 cases accepted more than six courses of neoadjuvant chemo-
therapy, including individualizedmanagement plan after six courses;
10 patients received chemotherapy only without surgical resec-
tion, and 9 patients underwent surgical resection at diagnosis, but
had recurrence or progressive disease in the post-operative treat-
ment and thus treated with other individualized regimens. The
individualized management included ICE regimen (carboplatin,
ifosfamide, and etoposide), C5VD regimen (cisplatin, 5-ﬂuorouracil,
vincristine, and doxorubicin), or cyclophosphamide combined with
topotecan.
Surgery
A total of 143 (93.5%) patients with HB underwent surgery; 88
of them (61.5%) had right hemihepatectomy, 35 (24.5%) had left
hemihepatectomy, and 20 (14.0%) cases had the other surgical ap-
proaches (the combined right and left hemihepatectomy, or hepatic
caudate lobectomy). Five patients had post-operative complica-
tions including biliary leakage (n = 2), peritonitis (n = 1), chylous
ascites (n = 1), and pneumonia (n = 1). There was no patient receiv-
ing liver transplantation in this study.
Treatment outcome
Of a total of 153 HB patients in this study, 106 (69.3%) achieved
complete remission (CR); one (0.6%) had stable disease (SD); 14 pa-
tients (9.2%) had progressive disease (PD), of which 5 abandoned
subsequent treatment, 1 lost in follow-up, 1 died, and 7 patients
were still alive; 21 patients (13.7%) relapsed with the median re-
currence time of 15.0 (4.0–36.97)months, 15 of them had recurrence
in liver, 3 in brain, and 3 in lungs, respectively, and among them 7
patients died in the following treatment, 3 cases abandoned and 1
case lost in follow-up respectively, the remaining 10 patients still
survived; 6 cases (3.9%) died during the course of this study, 3 cases
from primary disease, and 3 from sepsis; 2 patients (1.3%) aban-
doned the treatment due to ﬁnancial reasons and 3 cases (2.0%) were
lost in follow-up. There was no case with hearing loss, heart failure,
or other major organ failure.
Among the 23 patients with metastasis at diagnosis, the meta-
static loci in 8 cases (34.8%) completely disappeared after
chemotherapy and surgical resection and those patients achieved
complete remission. There were 7 cases (30.4%) whose metasta-
ses resolved after chemotherapy; however 4 cases relapsed at the
same loci and 3 patients at other location during the following treat-
ment. Eight cases (34.8%) had events during the treatment, two of
them died from primary disease and 6 patients developed progres-
sive disease.
Three patients had multinodular PRETEXT IV HB, two of them
had also extrahepatic disease. Even with chemotherapy and surgery,
one patient with extrahepatic disease died from disease progres-
sion and the remaining two remained alive.
There were 108 patients with PRETEXT III or IV in this group;
after more than two cycles of neoadjuvant chemotherapy, 69 of them
(63.9%) had complete surgical resection (COG I stage), 8 cases (7.4%)
Fig. 2. Treatment path and outcome of 153 HB patients. Ninety-nine patients received chemotherapy and ﬁfty-four cases underwent surgery at diagnosis. A total of 143
children had post-operative chemotherapy.
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had microscopic residual (COG II stage) and 4 cases (3.7%) had gross
tumor residual (COG III stage), 17 (15.7%) had metastasis, and 10
(9.3%) of them could not undergo surgery. Overall, half of the ad-
vanced HB patients had complete surgical resection after neoadjuvant
chemotherapy.
Survival analysis
The 6-year OS rate was 83.3 ± 3.1% (100% in PRETEXT I, 93.0 ± 4.8%
in PRETEXT II, 84.4 ± 4.5% in PRETEXT III, and 68.4 ± 7.4% in PRETEXT
IV (P = 0.013) (Fig. 3A and B), whereas the 6-year EFS rate was
71.0 ± 3.7% among all patients (100% in PRETEXT I, 89.4 ± 5.8% in
PRETEXT II, 73.2 ± 5.6% in PRETEXT III, and 43.3 ± 8.0% in PRETEXT
IV (P = 0.000) (Fig. 3D and E). The 6-year OS rates of standard-risk
and high-risk patients were 90.3 ± 2.9% and 67.6 ± 7.0% (P = 0.001),
respectively (Fig. 3C), while the 6-year EFS rates were 82.3 ± 3.8%
and 45.4 ± 7.5% (P = 0.000) (Fig. 3F). Patients treated under Wuhan
Protocol had better OS (Fig. 4A) and EFS rates as comparedwith those
patients treatedwith combined regimens (6-year OS rate: 87.6 ± 3.2%
vs. 72.7 ± 6.7%, P = 0.025; 6-year EFS rate: 78.9 ± 4.0% vs. 52.3 ± 7.6%,
P = 0.000). The 6-year OS rate for delayed surgery with neoadjuvant
chemotherapy (Fig. 4B) was 90.8 ± 3.1%, whereas 83.0 ± 5.2% in pa-
tients with primary surgery and post-operative chemotherapy.
Patients with chemotherapy only had an OS rate of mere 20.0 ± 12.6%
(P = 0.000).
The univariate analysis showed that female (6-year OS rate:
93.8 ± 3.5%, P = 0.027, Fig. 4C), patients under ﬁve years of age (6-
year OS rate: 85.0 ± 3.0%, P = 0.039, Fig. 4D), complete surgical
resection (6-year OS rate: 93.5 ± 2.4%, P = 0.000, Fig. 4E), and no me-
tastases at diagnosis (6-year OS rate: 89.0 ± 2.8%, P = 0.000, Fig. 4F)
had better prognosis as shown in Fig. 4. All above factors were drawn
into multivariate Cox proportional-hazards regression model,
which revealed that male (P = 0.039, 95%CI 1.04–5.50), PRETEXT III
(P = 0.019, 95%CI 1.27–14.90), PRETEXT IV (P = 0.034, 95%CI 1.11–
14.73), and incomplete surgical resection (P = 0.000, 95%CI 2.61–
15.10) could be considered as individual factors contributing to
poorer prognosis (Table 2).
Discussion
In this retrospective study, for the ﬁrst time, we reported a large
number of pediatric HB patients in China treated under Wuhan Pro-
tocol. It was also the ﬁrst time for CCCG to summarize the current
therapy for HB children in China. Compared to acute lymphocytic
leukemia and brain tumor, which are common childhood malig-
nancies [11], the incidence of HB is extremely low. Therefore,
Fig. 3. Kaplan–Meier of 6-year OS and 6-year EFS rates. (A) The 6-year OS rate of all patients was 83.3 ± 3.1%; (B) OS rates stratiﬁed by PRETEXT stage: 100% in PRETEXT I,
93.0 ± 4.8% in PRETEXT II, 84.4 ± 4.5% in PRETEXT III, and 68.4 ± 7.4% in PRETEXT IV (P = 0.013); (C) OS rates stratiﬁed by SR and HR risk groups: 90.3 ± 2.9% in SR group and
67.6 ± 7.0% in HR group (P = 0.001); (D) The 6-year EFS rate for all patients was 71.0 ± 3.7%; (E) EFS rates stratiﬁed by PRETEXT stage: 100% in PRETEXT I, 89.4 ± 5.8% in PRETEXT
II, 73.2 ± 5.6% in PRETEXT III, and 43.3 ± 8.0% in PRETEXT IV (P = 0.000); (F) EFS rates stratiﬁed by SR and HR risk groups: 82.3 ± 3.8% and 45.4 ± 7.5% (P = 0.000), respectively.
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multi-center cooperation plays an important role in standardizing
HB treatment protocols. In the past 40 years, several major HB study
groups have been established [12–15]. In order to facilitate better
international communication and cooperation, the Children’s Hepatic
tumor International Collaboration (CHIC) was formed to combine
the results of multi-center trials by SIOPEL, COG, German Liver Tumor
Study (GPOH), and Japanese Study Group for Pediatric Liver Tumor
(JPLT) [4,16]. CCCG was established in 1997 in China, and the liver
tumor subgroup began collecting the data on HB patients since 2006,
and 13 member hospitals participated in this effort.
Multidisciplinary cooperation is also the fundamental in HB treat-
ment, especially neoadjuvant chemotherapy, which is the cornerstone
in the development of solid tumor treatment. In 1982, Evans et al.
[17] ﬁrst suggested that when pre-operative chemotherapy
(neoadjuvant chemotherapy) was used in HB treatment, the 3-year
OS rate had risen from 20–25% to 30–40%. Recently, a series of clin-
ical trials demonstrated that complete resection rate was over 90%
after neoadjuvant chemotherapy [10]. The 3-year OS rate could also
be as high as 70–80% in high-risk group [18]. In our study, 63.9%
advanced patients achieved complete surgical resection (COG stage
I) after neoadjuvant chemotherapy. Comparing the survival rates
between delayed surgery (after pre-operative neoadjuvant chemo-
therapy) and primary surgery (without pre-operative but post-
operative chemotherapy), the former group had a better survival
rate (90.8 ± 3.1% vs. 83.0 ± 5.2%, P = 0.000). Complete resection plays
a key role in treating HB and enables an optimal outcome [19]; it
also strongly suggests that neoadjuvant chemotherapy before surgery
signiﬁcantly improves total resection rate as well as the survival rate
in children with HB. As compared with complete surgical resec-
tion, the patients who had partial tumor resection achieved lower
6-year OS rate (57.1 ± 7.8% versus 93.5 ± 2.4%, P = 0.000). Besides con-
ventional surgery for tumor resection, new surgical approaches
Fig. 4. The univariate analysis of HB estimated by 6-year OS rate. (A) Different chemotherapy regimens (C5V/PLADO vs. C5V/PLADO combined with others: 87.6 ± 3.2% vs.
72.7 ± 6.7%, P = 0.025); (B) Treatment modalities (delayed surgery vs. primary surgery vs. chemotherapy only: 90.8 ± 3.1% vs. 83.0 ± 5.2% vs. 20.0 ± 12.6%, P = 0.000); (C) Gender
(female vs. male: 93.8 ± 3.5% vs. 78.4 ± 4.1%, P = 0.027); (D) Age (age under ﬁve years vs. age ﬁve years or above: 85.0 ± 3.0% vs. 60.0 ± 15.5%, P = 0.039; (E) Surgical respect-
ability (complete surgical resection vs. incomplete surgical resection: 93.5 ± 2.4% vs. 57.1 ± 7.8%, P = 0.000); (F) Metastasis (without metastasis vs. with metastasis: 89.0 ± 2.8%
vs. 48.2 ± 13.6%, P = 0.000).
Table 2
The multivariate analysis with COX regression.
Factor Number HRa 95% CIa P valueb
Male 104 2.40 1.04–5.50 0.039
Age 5 years old and over 10 1.15 0.44–3.00 0.781
PRETEXT III 64 4.35 1.27–14.90 0.019
PRETEXT IV 44 4.17 1.11–14.73 0.034
Incomplete resection 109 6.27 2.61–15.10 0.000
a HR stands for hazard ratio, CI stands for conﬁdence interval.
b P < 0.050 indicates statistical signiﬁcance at the 5% level.
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should be explored, such as liver transplantation (LT) [20],
transcatheter arterial chemoembolization [21] and high intensity
focused ultrasound [22]. LT has become the standard treatment for
multinodular HB since 2004 [23] and remained currently recom-
mended in patients with multinodular PRETEXT IV HB without
extrahepatic disease, even though some of these children were prob-
ably over-treated. However, in this study there was no patient who
received LT due to the limited number of medical centers that are
qualiﬁed to perform LT. In addition, the rarity of appropriate donors
and the high cost associated to LT are two other additional factors
that directly affect LT in China. Furthermore, it needs an accurate
evaluation of the beneﬁts for each case to balance the chances of
cure versus organ availability [24].
With the use of neoadjuvant chemotherapy and surgery, the
6-year OS and EFS rates were 83.3 ± 3.1% and 71.0 ± 3.7%, respec-
tively, in this cohort. Recent literature review of clinical trials revealed
that the majority of 3-year OS rates were above 80% [4]. In SIOPEL,
3-year OS rates for standard-risk and high-risk groups were 93–
95% (n = 255) and 83% (n = 62), respectively [18,25]. In JPLT study,
the 5-year OS rate for 212 patients with HB was 80.9% [26]. The
3-year OS rate for patients in GPOH was 89%, and for standard-
risk group and high-risk group were 90% and 55%, respectively [14].
The survival rate in our study was similar to that obtained by other
international study groups, which indicated the effectiveness of
current protocol in China. To further analyze and optimize Wuhan
Protocol, all patients were retrospectively classiﬁed into the stan-
dard and high-risk groups; the 6-year OS rates were 90.3 ± 2.9% and
67.6 ± 7.0% (P = 0.001), respectively. Standard-risk group with C5V
regimen had achieved a satisfactory result; however, the progno-
sis of high-risk group was still gloomy. We believe it is necessary
to adjust the treatment intensity based on risk-stratiﬁcation, which
means reducing the intensity in standard-risk group and increas-
ing the intensity in high-risk group.
Some adverse factors that produce poor prognosis in HB had been
identiﬁed, such as age (above 5 years old), PRETEXT stage (III or IV)
[27], pathology subtypes (the SCU type) [28], serum AFP level (AFP
<100 ng/mL) [29], and metastasis [30]. We have also analyzed the
relationship between prognosis and these factors, such as gender,
age, PRETEXT stage, COG stage, pathology subtypes, AFP levels and
metastasis at diagnosis. The results demonstrated that female, age
over 5 years, PRETEXT III, PRETEXT IV, incomplete surgical resec-
tion, and with metastasis had poorer prognosis; our ﬁndings are in
agreement with those reported previously. In our cohort, only 2 pa-
tients were diagnosed with SCU subtype and died for relapse during
follow-up. There were two patients whose AFP was <100 ng/mL at
diagnosis, one died during follow-up due to relapse, and another
is still surviving.
The treatment of HB has been making great progress in the past
forty years. The preliminary results of Wuhan Protocol demon-
strated reduced side-effects and similar OS or EFS rate compared
to those in developed countries. However, standardizing surgical re-
section, LT, reﬁning risk stratiﬁcation, and risk-based chemotherapy
remain to be further optimized.
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